Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.80 USD
Change Today -0.41 / -2.89%
Volume 1.7K
As of 10:27 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by ASTELLAS PHARMA INC-UNSP ADR (ALPMY) in the last 6 months

Announced 07/31/15
28.21B for Astellas Pharma, Inc.
Buyback

Astellas Pharma Inc. (TSE:4503) announces a share repurchase program. Under the program, the company will repurchase up to 15,000,000 shares, representing 0.69% of its outstanding share capital, for a total cost of ¥30,000 million. The purpose of the plan is to improve capital efficiency and shareholder return. The repurchases will be made until September 11, 2015. As of July 31, 2015, the company had 2,173,198,302 shares outstanding and 48,624,873 shares in treasury. The ...
Read More


ALPMY's price was unchanged after the transaction was announced on 07/31/15.
 
Announced 05/29/15
16.00M for Kanyos Bio, Inc.
Private Placement

Kanyos Bio, Inc. announced that it will receive $16,409,144 in funding on May 29, 2015. The company will issue common stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. On June 2, 2015, the company announced that the transaction includes participation from new investors Astellas Pharma, Inc., Novo A/S, Versant Ventures, L.P., a fund managed by Versant Ventures, Inc., Novartis Venture Fund, a fund managed ...
Read More


ALPMY's price was unchanged after the transaction was announced on 05/29/15.
Investor / Buyer
Astellas Pharma, Inc.
Novartis Venture Fund
Novartis Venture Funds
Novo A/S
Versant Ventures, Inc.
Versant Ventures, L.P.
 
Announced 05/26/15
35.62B for Astellas Pharma, Inc.
Buyback

Astellas Pharma Inc. (TSE:4503) announces a share repurchase program. Under the program, the company will repurchase up to 20,000,000 shares, representing 0.91% of its outstanding share capital, for a total cost of ¥40,000 million. The purpose of the plan is to improve capital efficiency and shareholder return. The repurchases will be made until July 24, 2015. As of March 31, 2015, the company had 2,193,141,515 shares outstanding and 66,681,660 shares in treasury. The ...
Read More


ALPMY's price was unchanged after the transaction was announced on 05/26/15.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALPMY:US $13.80 USD -0.41

ALPMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $135.38 USD -1.15
Boston Scientific Corp $16.36 USD -0.17
CSL Ltd A$90.18 AUD +0.16
Mylan NV $47.70 USD +0.28
Solvay SA €102.95 EUR -1.70
View Industry Companies
 

Industry Analysis

ALPMY

Industry Average

Valuation ALPMY Industry Range
Price/Earnings 26.3x
Price/Sales 2.9x
Price/Book 2.8x
Price/Cash Flow 20.7x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC-UNSP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.